Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Charter Communications Inc (CHTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Charter Communications Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.1 (market cap $29.60B), while Charter Communications Inc trades at $150.06 (market cap $18.81B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Charter Communications Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CHTR | |
|---|---|---|
Market Cap | $29.60B | $18.81B |
Sector | Health | Media |
52-Week High | $491.22 | $282.74 |
52-Week Low | $205.48 | $123.31 |
Enterprise Value | $27.56B | $115.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Charter Communications (CHTR) trades at $153.29, up 0.47% today, near its pivot point of $152. The stock shows mixed technical signals with a bullish moving average trend but bearish oscillators. Fundamentally, it trades at low valuation multiples (P/E 4.1, P/S 0.37) with solid profitability (ROE 29.7%, net margin 9.05%), though Q1 2026 earnings missed expectations. Recent news highlights debt refinancing activities and competitive pressures in broadband.
Outlook: CHTR presents a value opportunity with deep discount to historical multiples, supported by strong cash flow and buybacks, but faces headwinds from subscriber losses and high debt load. Risks include fiber competition and revenue declines, while analyst consensus leans bullish with a $166.18 price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →
